0 516

Cited 35 times in

Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study.

Authors
 Man Fung Yuen  ;  Sang Hoon Ahn  ;  Kwan Sik Lee  ;  Soon Ho Um  ;  Mong Cho  ;  Seung Kew Yoon  ;  Jin Woo Lee  ;  Neung Hwa Park  ;  Young Oh Kweon  ;  Joo Hyun Sohn  ;  Jiyoon Lee  ;  Jeong Ae Kim  ;  Ching Lung Lai  ;  Kwang Hyub Han 
Citation
 JOURNAL OF HEPATOLOGY, Vol.62(3) : 526-532, 2015 
Journal Title
JOURNAL OF HEPATOLOGY
ISSN
 0168-8278 
Issue Date
2015
MeSH
Adult ; Alanine Transaminase/blood ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use* ; Carnitine/deficiency ; Carnitine/metabolism ; DNA, Viral/blood ; DNA, Viral/genetics ; Female ; Guanine/adverse effects ; Guanine/analogs & derivatives* ; Guanine/therapeutic use ; Hepatitis B e Antigens/blood ; Hepatitis B virus/genetics ; Hepatitis B virus/isolation & purification ; Hepatitis B, Chronic/drug therapy* ; Hepatitis B, Chronic/metabolism ; Hepatitis B, Chronic/virology ; Humans ; Male ; Middle Aged ; Organophosphonates/adverse effects ; Organophosphonates/therapeutic use* ; Seroconversion ; Time Factors ; Treatment Outcome ; Young Adult
Keywords
Besifovir ; Entecavir ; LB80380 ; Resistance ; Safety ; Viral suppression
Abstract
BACKGROUND & AIMS: We aimed to compare the viral suppression, safety and rate of drug resistance between besifovir (a new acyclic nucleotide analogue) and entecavir.
METHODS: Treatment-naïve chronic hepatitis B patients receiving besifovir 90 mg (n=31), 150 mg (n=28) and entecavir 0.5 mg (n=30) were monitored for liver biochemistry, viral serology, HBV DNA levels, development of drug resistance mutations, and adverse events throughout 96 weeks of treatment.
RESULTS: The mean decline of HBV DNA levels from baseline to week 96 were 5.29, 5.15, and 5.67 logs IU/ml for patients receiving besifovir 90 mg, 150 mg and entecavir 0.5 mg, respectively (p>0.05). Undetectable HBV DNA (<20 IU/ml) were achieved in 80.7%, 78.6%, and 80%; ALT normalization in 90.3%, 78.6%, and 93.3%; and loss of HBeAg in 20%, 21.4%, and 22.2% of patients respectively (all p>0.05). One patient receiving besifovir 90 mg had a virological breakthrough due to drug non-compliance. No patient developed drug resistance mutations. Ten patients had serious adverse events, which were not related to the study medications. The most common side effect related to besifovir was carnitine depletion. Carnitine supplements were prescribed to 83.9% and 100% of patients, who had low carnitine level for any one time during follow-up, receiving besifovir 90 mg and 150 mg respectively. No patient had increased creatinine>0.5 mg/dl from baseline.
CONCLUSIONS: Besifovir had the same antiviral property as compared to entecavir over 96 weeks of treatment for chronic hepatitis B patients. Besifovir was well tolerated and also had a good clinical safety profile.
Full Text
http://www.sciencedirect.com/science/article/pii/S0168827814007879
DOI
10.1016/j.jhep.2014.10.026
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Kwan Sik(이관식) ORCID logo https://orcid.org/0000-0002-3672-1198
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/140453
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links